RDHL (Redhill Biopharma) Other Current Receivables : $1.03 Mil (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Other Current Receivables?

Redhill Biopharma's Other Current Receivables for the quarter that ended in Dec. 2024 was $1.03 Mil.

Redhill Biopharma's quarterly Other Current Receivables increased from Dec. 2023 ($1.49 Mil) to Jun. 2024 ($2.91 Mil) but then stayed the same from Jun. 2024 ($2.91 Mil) to Dec. 2024 ($1.03 Mil).

Redhill Biopharma's annual Other Current Receivables declined from Dec. 2022 ($3.35 Mil) to Dec. 2023 ($1.49 Mil) and declined from Dec. 2023 ($1.49 Mil) to Dec. 2024 ($1.03 Mil).

Redhill Biopharma Other Current Receivables Historical Data

The historical data trend for Redhill Biopharma's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Other Current Receivables Chart

Redhill Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Current Receivables

Get a 7-Day Free Trial

0.63

0.85

3.35

1.49

1.03

Redhill Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23	Jun24	Dec24
Other Current Receivables	Get a 7-Day Free Trial															5.17	3.05	1.49	2.91	1.03

Redhill Biopharma Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

Redhill Biopharma Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Redhill Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Other Current Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.